UK would not have approved Valneva COVID vaccine, health secretary says – Reuters

January 27, 2022

The logo of Valneva SE is pictured at the company's headquarters in Saint-Herblain, near Nantes, France, September 13, 2021. REUTERS/Stephane Mahe
LONDON, Sept 14 (Reuters) – Britain cancelled its contract for about 100 million doses of a COVID-19 vaccine being developed by France's Valneva (VLS.PA) in part because it was clear it would not be approved for use in the country, UK Health Secretary Sajid Javid said on Tuesday.
"There are commercial reasons that we have cancelled the contract, but what I can tell her is that it was also clear to us that the vaccine in question that the company was developing would not get approval by the MHRA here in the UK," he said in response to a question from a Scottish lawmaker.
Shares in Valneva plunged 35% on Monday after it said the British government had ended a COVID-19 vaccine supply deal that could have been worth up to 1.4 billion euros ($1.65 billion).
The shares made up some of the lost ground on Tuesday, regaining more than 8%, to close at 12.60 euros. At that level, they're still up 62.6% since the start of 2021.
A French government source told Reuters discussions between Valneva and the European Commission were ongoing and advanced.
"The EU is still interested in this vaccine", the source said, adding Valneva was also being positioned, in France at least, as a booster shot, same as would be Sanofi (SASY.PA), which has yet to have COVID-19 shot authorised.
Valneva's COVID-19 vaccine candidate, VLA 2001, relies on an inactivated virus, similar to flu vaccines, and is seen by some as having the potential to win over people wary of vaccines that use new mRNA technology.
The company said on Monday that the British government had alleged it was in breach of its obligations under the supply agreement. It said it strenuously denied the charge.
The vaccine is being produced in Livingston, Scotland, using an adjuvant made by U.S. company Dynavax (DVAX.O). The facility has capacity to produce around 200 million doses in 2022.
Valneva has said the UK government had options that could have brought the order to 190 million doses by 2025.
Javid said the British and Scottish governments would be working together to see what they could do to secure the future of the facility.
Our Standards: The Thomson Reuters Trust Principles.
Keep up with the latest medical breakthroughs, healthcare trends, pharmaceutical news and more.
Subscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Article Tags:
Article Categories:
Health · News

Leave a Reply

Your email address will not be published.